xCELLigence System Evaluated in EU Project to Replace Animal Experiments in Cosmetics Industry
PENZBERG, Germany, March 28, 2012 /PRNewswire/ –
Roche’s xCELLigence RTCA
[https://www.roche-applied-science.com/sis/xcelligence/index.jsp?&id=xcect_000000 ] System
is being used in the European Union’s SEURAT (Safety Evaluation Ultimately Replacing
Animal Testing) initiative to run five years from 2011 to 2016. As of 2013, animal
experiments are no longer permitted for use in toxicology testing in the cosmetic
industry. Significant progress has been made in recent years to develop alternatives to in
vivo toxicity tests for assessing human safety of new products and their ingredients. At
present, it is however not possible to completely replace animal testing. This is
especially true when testing the effects of repeated doses over longer periods of time.
A SEURAT-sponsored research team comprising Paul Jennings at the Department of
Physiology and Medical Physics, Innsbruck Medical University (Austria), and Alex Seiler
and Manfred Watzele at Roche Penzberg (Germany), used continuous real-time impedance
measurements with the xCELLigence System to investigate renal epithelial monolayer
formation and barrier function. To test repeated dose effects, a human renal proximal
tubule cell line (RPTEC/TERT1, Evercyte GmbH Vienna) was cultured on electronic
sensor-containing E-Plates 96. Cell impedance was monitored over several weeks in culture,
and the effect of nephrotoxin treatment on cell impedance was investigated. Findings
showed that the three different nephrotoxins initially increased impedance values as
epithelial cell morphology was altered, followed by a decrease in impedance due to cell
The xCELLigence System was shown to be a sensitive, non-invasive tool for monitoring
repeated dose effects on epithelial cell function and cytotoxicity. Unlike the more
laborious transepithelial electrical resistance (TEER) assay, this in vitro assay is a
simple, automated, non-invasive, functional readout with very high temporal resolution.
Assays such as this will we be beneficial in efforts to replace animal testing for
long-term repeat dose regimes.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare
with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest
biotech company with truly differentiated medicines in oncology, virology, inflammation,
metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based
cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare
strategy aims at providing medicines and diagnostic tools that enable tangible
improvements in the health, quality of life and survival of patients. In 2011, Roche had
over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group
posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned
member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For
more information: http://www.roche.com.
XCELLIGENCE is a trademark of Roche.
E-PLATE is a registered trademarks of ACEA Biosciences, Inc. in the US
For life science research only. Not for use in diagnostic procedures.
For further information please contact: Roche Diagnostics Dr. Burkhard Ziebolz Phone: +49-8856-604830 Email: firstname.lastname@example.org
SOURCE Roche Diagnostics GmbH